Andreas Suhrbier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1910240/publications.pdf

Version: 2024-02-01

145 papers 8,372 citations

51 h-index 84 g-index

160 all docs

160 does citations

160 times ranked 8241 citing authors

#	Article	IF	CITATIONS
1	Ambient Temperature Stable, Scalable COVIDâ€19 Polymer Particle Vaccines Induce Protective Immunity. Advanced Healthcare Materials, 2022, 11, e2102089.	7.6	14
2	Microplastic consumption induces inflammatory signatures in the colon and prolongs a viral arthritis. Science of the Total Environment, 2022, 809, 152212.	8.0	38
3	The Chimeric Binjari-Zika Vaccine Provides Long-Term Protection against ZIKA Virus Challenge. Vaccines, 2022, 10, 85.	4.4	10
4	Pathophysiological Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy Enables Rapid and Robust Saliva Screening for COVID-19. Biomedicines, 2022, 10, 351.	3.2	14
5	Widespread discrepancy in Nnt genotypes and genetic backgrounds complicates granzyme A and other knockout mouse studies. ELife, 2022, 11 , .	6.0	16
6	Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. Theranostics, 2022, 12, 2811-2832.	10.0	8
7	Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction. ACS Central Science, 2022, 8, 527-545.	11.3	62
8	Phase 1 success for a trivalent vaccine for the equine encephalitis viruses. Lancet Infectious Diseases, The, 2022, , .	9.1	0
9	An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice. Journal of Virology, 2022, 96, .	3.4	6
10	Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet Infectious Diseases, The, 2021, 21, e123-e133.	9.1	38
11	Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures. PLoS Pathogens, 2021, 17, e1009215.	4.7	13
12	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 2021, 184, 2167-2182.e22.	28.9	131
13	The dinucleotide composition of the Zika virus genome is shaped by conflicting evolutionary pressures in mammalian hosts and mosquito vectors. PLoS Biology, 2021, 19, e3001201.	5 . 6	15
14	Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discovery, 2021, 7, 37.	6.7	11
15	Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives. Virology Journal, 2021, 18, 123.	3.4	21
16	A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. Nature Communications, 2021, 12, 3431.	12.8	89
17	ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. PLoS Pathogens, 2021, 17, e1009723.	4.7	28
18	Neuroinvasiveness of the MR766 strain of Zika virus in IFNAR-/-Âmice maps to prM residues conserved amongst African genotype viruses. PLoS Pathogens, 2021, 17, e1009788.	4.7	18

#	Article	IF	Citations
19	Embryonic Stage of Congenital Zika Virus Infection Determines Fetal and Postnatal Outcomes in Mice. Viruses, 2021, 13, 1807.	3.3	2
20	Temperature modulates immune gene expression in mosquitoes during arbovirus infection. Open Biology, 2021, 11, 200246.	3.6	21
21	A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine. Vaccines, 2020, 8, 368.	4.4	24
22	Zika Virus sfRNA Plays an Essential Role in the Infection of Insects and Mammals. Proceedings (mdpi), 2020, 50, .	0.2	0
23	A Zika Vaccine Generated Using the Chimeric Insect-Specific Binjari Virus Platform Protects against Fetal Brain Infection in Pregnant Mice. Vaccines, 2020, 8, 496.	4.4	15
24	Sequencing of Historical Isolates, K-mer Mining and High Serological Cross-Reactivity with Ross River Virus Argue against the Presence of Getah Virus in Australia. Pathogens, 2020, 9, 848.	2.8	10
25	Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models. Vaccines, 2020, 8, 209.	4.4	21
26	The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. Npj Vaccines, 2020, 5, 44.	6.0	17
27	SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages. Scientific Reports, 2019, 9, 12421.	3.3	26
28	Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nature Reviews Rheumatology, 2019, 15, 597-611.	8.0	117
29	Long noncoding RNAs are involved in multiple immunological pathways in response to vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17121-17126.	7.1	58
30	Systems analysis of subjects acutely infected with the Chikungunya virus. PLoS Pathogens, 2019, 15, e1007880.	4.7	33
31	Determinants of Zika virus host tropism uncovered by deep mutational scanning. Nature Microbiology, 2019, 4, 876-887.	13.3	50
32	Inhibition of Interleukinâ€1β Signaling by Anakinra Demonstrates a Critical Role of Bone Loss in Experimental Arthritogenic Alphavirus Infections. Arthritis and Rheumatology, 2019, 71, 1185-1190.	5.6	17
33	Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate. Frontiers in Immunology, 2019, 10, 2736.	4.8	30
34	A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus. Science Translational Medicine, 2019, 11, .	12.4	70
35	SerpinB2 deficiency in mice reduces bleeding times via dysregulated platelet activation. Platelets, 2019, 30, 658-663.	2.3	6
36	Granzyme A in Chikungunya and Other Arboviral Infections. Frontiers in Immunology, 2019, 10, 3083.	4.8	30

#	Article	IF	CITATIONS
37	Interpreting paired serology for Ross River virus and Barmah Forest virus diseases. Australian Journal of General Practice, 2019, 48, 645-649.	0.8	12
38	Mapping the virome in wild-caught Aedes aegypti from Cairns and Bangkok. Scientific Reports, 2018, 8, 4690.	3.3	84
39	IFN Regulatory Factor 3 Balances Th1 and T Follicular Helper Immunity during Nonlethal Blood-Stage <i>Plasmodium (i) Infection. Journal of Immunology, 2018, 200, 1443-1456.</i>	0.8	31
40	A vaccinia-based singleÂvector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nature Communications, 2018, 9, 1230.	12.8	71
41	Fetal Brain Infection Is Not a Unique Characteristic of Brazilian Zika Viruses. Viruses, 2018, 10, 541.	3.3	15
42	Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert Review of Vaccines, 2018, 17, 925-934.	4.4	31
43	Ilheus and Saint Louis encephalitis viruses elicit cross-protection against a lethal Rocio virus challenge in mice. PLoS ONE, 2018, 13, e0199071.	2.5	13
44	New genotypes of Liao ning virus (LNV) in Australia exhibit an insect-specific phenotype. Journal of General Virology, 2018, 99, 596-609.	2.9	14
45	<i>De Novo</i> Generation and Characterization of New Zika Virus Isolate Using Sequence Data from a Microcephaly Case. MSphere, 2017, 2, .	2.9	47
46	Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports, 2017, 7, 41537.	3.3	14
47	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nature Microbiology, 2017, 2, 1435-1445.	13.3	77
48	Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology. Molecular Therapy, 2017, 25, 2332-2344.	8.2	18
49	Lower temperatures reduce type I interferon activity and promote alphaviral arthritis. PLoS Pathogens, 2017, 13, e1006788.	4.7	37
50	Tattoo removal with ingenol mebutate. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 205-210.	1.8	3
51	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation. PLoS Pathogens, 2017, 13, e1006155.	4.7	98
52	Chikungunya virus, risks and responses for Australia. Australian and New Zealand Journal of Public Health, 2016, 40, 207-209.	1.8	4
53	SerpinB2 Deficiency Results in a Stratum Corneum Defect and Increased Sensitivity to Topically Applied Inflammatory Agents. American Journal of Pathology, 2016, 186, 1511-1523.	3.8	13
54	Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Scientific Reports, 2016, 6, 36658.	3.3	11

#	Article	IF	Citations
55	Chikungunya virus transmission between Aedes albopictus and laboratory mice. Parasites and Vectors, 2016, 9, 555.	2.5	16
56	IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate. PLoS ONE, 2016, 11, e0153975.	2.5	18
57	SerpinB2 (PAI-2) Modulates Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion Formation. PLoS ONE, 2015, 10, e0130136.	2.5	30
58	A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates. Journal of Infectious Diseases, 2015, 212, S368-S371.	4.0	38
59	Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 2015, 203, 72-76.	2.2	7
60	Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm. Vaccine, 2015, 33, 5172-5180.	3.8	12
61	Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple applications. Journal of General Virology, 2015, 96, 507-512.	2.9	26
62	Chikungunya virus non-structural protein 2-mediated host shut-off disables the unfolded protein response. Journal of General Virology, 2015, 96, 580-589.	2.9	60
63	Infectious Chikungunya Virus in the Saliva of Mice, Monkeys and Humans. PLoS ONE, 2015, 10, e0139481.	2.5	32
64	Multiple Immune Factors Are Involved in Controlling Acute and Chronic Chikungunya Virus Infection. PLoS Neglected Tropical Diseases, 2014, 8, e3354.	3.0	145
65	Increase in DNA vaccine efficacy by virosome delivery and coâ€expression of a cytolytic protein. Clinical and Translational Immunology, 2014, 3, e18.	3.8	19
66	Tumor cellâ€expressed SerpinB2 is present on microparticles and inhibits metastasis. Cancer Medicine, 2014, 3, 500-513.	2.8	31
67	CCR2 Deficiency Promotes Exacerbated Chronic Erosive Neutrophil-Dominated Chikungunya Virus Arthritis. Journal of Virology, 2014, 88, 6862-6872.	3.4	117
68	<scp>DNA</scp> vaccines encoding membraneâ€bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 2014, 44, 1992-2002.	2.9	20
69	Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 2014, 192, 25-33.	2.2	6
70	IRF-3, IRF-7, and IPS-1 Promote Host Defense against Acute Human Metapneumovirus Infection in Neonatal Mice. American Journal of Pathology, 2014, 184, 1795-1806.	3.8	22
71	Induction of antigenâ€positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 2014, 92, 359-367.	2.3	29
72	Are Impact Factors corrupting truth and utility in biomedical research?. Vaccine, 2013, 31, 6041-6042.	3.8	4

#	Article	IF	Citations
73	Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Archives of Dermatological Research, 2013, 305, 79-83.	1.9	27
74	Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clinical Immunology, 2013, 149, 487-497.	3.2	67
75	A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease. PLoS Neglected Tropical Diseases, 2013, 7, e2423.	3.0	99
76	Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells. PLoS Neglected Tropical Diseases, 2013, 7, e2124.	3.0	122
77	Induction of SerpinB2 and Th1/Th2 Modulation by SerpinB2 during Lentiviral Infections In Vivo. PLoS ONE, 2013, 8, e57343.	2.5	14
78	Ingenol Mebutate Field-Directed Treatment of UVB-Damaged Skin Reduces Lesion Formation and Removes Mutant p53 Patches. Journal of Investigative Dermatology, 2012, 132, 1263-1271.	0.7	58
79	Interferon Response Factors 3 and 7 Protect against Chikungunya Virus Hemorrhagic Fever and Shock. Journal of Virology, 2012, 86, 9888-9898.	3.4	157
80	Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3553-3563.	6.7	114
81	Guideâ€wire fragment embolisation in paediatric peripherally inserted central catheters. Medical Journal of Australia, 2012, 196, 250-255.	1.7	4
82	Arthritogenic alphavirusesâ€"an overview. Nature Reviews Rheumatology, 2012, 8, 420-429.	8.0	374
83	A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine, 2011, 29, 2803-2809.	3.8	107
84	The Role of SerpinB2 in Immunity. Critical Reviews in Immunology, 2011, 31, 15-30.	0.5	64
85	Primeâ€boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis. Immunology and Cell Biology, 2011, 89, 426-436.	2.3	4
86	Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2. Experimental Cell Research, 2011, 317, 338-347.	2.6	9
87	Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis and Rheumatism, 2011, 63, 488-491.	6.7	34
88	Identification and Characterization of a Ross River Virus Variant That Grows Persistently in Macrophages, Shows Altered Disease Kinetics in a Mouse Model, and Exhibits Resistance to Type I Interferon. Journal of Virology, 2011, 85, 5651-5663.	3.4	23
89	Nanopatchâ€Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice. Small, 2010, 6, 1776-1784.	10.0	150
90	Vaccine delivery: Nanopatch-Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice (Small 16/2010). Small, 2010, 6, n/a-n/a.	10.0	0

#	Article	IF	Citations
91	Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. Journal of Clinical Investigation, 2010, 120, 894-906.	8.2	447
92	Chikungunya Virus Nonstructural Protein 2 Inhibits Type I/II Interferon-Stimulated JAK-STAT Signaling. Journal of Virology, 2010, 84, 10877-10887.	3.4	209
93	A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity. Journal of Immunology, 2010, 184, 2663-2670.	0.8	106
94	Chikungunya Virus Arthritis in Adult Wild-Type Mice. Journal of Virology, 2010, 84, 8021-8032.	3.4	366
95	Potent Inhibition of HIV-1 Replication by a Tat Mutant. PLoS ONE, 2009, 4, e7769.	2.5	47
96	The immunobiology of viral arthritides. , 2009, 124, 301-308.		51
97	Amelioration of alphavirusâ€induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis and Rheumatism, 2009, 60, 2513-2523.	6.7	82
98	Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine, 2009, 27, 3053-3062.	3.8	35
99	Ticks Associated with Macquarie Island Penguins Carry Arboviruses from Four Genera. PLoS ONE, 2009, 4, e4375.	2.5	66
100	Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nature Biotechnology, 2008, 26, 571-577.	17.5	62
101	Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine, 2008, 26, 3268-3276.	3.8	17
102	Macrophageâ€Derived Proinflammatory Factors Contribute to the Development of Arthritis and Myositis after Infection with an Arthrogenic Alphavirus. Journal of Infectious Diseases, 2008, 197, 1585-1593.	4.0	124
103	Phase I Trial of a CD8 ⁺ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis. Journal of Virology, 2008, 82, 1448-1457.	3.4	133
104	SerpinB2 Protection of Retinoblastoma Protein from Calpain Enhances Tumor Cell Survival. Cancer Research, 2008, 68, 5648-5657.	0.9	58
105	Human Papillomavirus E7 Requires the Protease Calpain to Degrade the Retinoblastoma Protein. Journal of Biological Chemistry, 2007, 282, 37492-37500.	3.4	34
106	Toward the Development of Prophylactic and Therapeutic Human Papillomavirus Type-16 Lipopeptide Vaccines. Journal of Medicinal Chemistry, 2007, 50, 4721-4727.	6.4	45
107	Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. Cellular Signalling, 2007, 19, 1279-1289.	3.6	94
108	Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunology, Immunotherapy, 2006, 55, 933-947.	4.2	7

#	Article	IF	CITATIONS
109	Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate. Journal of Immunology, 2006, 177, 8123-8132.	0.8	165
110	Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opinion on Biological Therapy, 2006, 6, 135-145.	3.1	70
111	SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication. Journal of Biological Chemistry, 2006, 281, 31348-31358.	3.4	8
112	From mice to humans – murine intelligence for human CD8+T cell vaccine design. Expert Opinion on Biological Therapy, 2005, 5, 263-271.	3.1	10
113	Heat Shock Protein 10 Inhibits Lipopolysaccharide-induced Inflammatory Mediator Production. Journal of Biological Chemistry, 2005, 280, 4037-4047.	3.4	158
114	Silencing of Integrated Human Papillomavirus Type 18 Oncogene Transcription in Cells Expressing SerpinB2. Journal of Virology, 2005, 79, 4246-4256.	3.4	13
115	Tetracycline-Inducible Packaging Cell Line for Production of Flavivirus Replicon Particles. Journal of Virology, 2004, 78, 531-538.	3.4	66
116	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15440-15445.	7.1	226
117	NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors. Clinical Cancer Research, 2004, 10, 2879-2890.	7.0	84
118	Antitumor Activity of 3-Ingenyl Angelate. Cancer Research, 2004, 64, 2833-2839.	0.9	239
119	Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Current Opinion in Rheumatology, 2004, 16, 374-379.	4.3	143
120	Corticosteroid Therapy in an Alphaviral Arthritis. Journal of Clinical Rheumatology, 2004, 10, 326-330.	0.9	31
121	Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends in Immunology, 2003, 24, 165-168.	6.8	57
122	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. Molecular and Cellular Biology, 2003, 23, 6520-6532.	2.3	64
123	Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias. Journal of Immunology, 2003, 170, 2599-2604.	0.8	53
124	Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development. Journal of Virology, 2003, 77, 7796-7803.	3.4	45
125	Polytope vaccines for the codelivery of multiple CD8T-cell epitopes. Expert Review of Vaccines, 2002, 1, 207-213.	4.4	36
126	Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8 + T-Cell Immunity. Journal of Virology, 2002, 76, 3791-3799.	3.4	70

#	Article	IF	CITATIONS
127	Natural history of Ross River virusâ€induced epidemic polyarthritis. Medical Journal of Australia, 2002, 177, 356-360.	1.7	99
128	Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood, 2001, 98, 3739-3744.	1.4	112
129	Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. European Journal of Immunology, 2001, 31, 3064-3074.	2.9	38
130	Arbovirus of Marine Mammals: a New Alphavirus Isolated from the Elephant Seal Louse, Lepidophthirus macrorhini. Journal of Virology, 2001, 75, 4103-4109.	3.4	109
131	Delayed Emergence of Bovine Leukemia Virus after Vaccination with a Protective Cytotoxic T Cell-Based Vaccine. AIDS Research and Human Retroviruses, 2001, 17, 1447-1453.	1.1	11
132	Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines. European Journal of Immunology, 2000, 30, 671-677.	2.9	22
133	An Arthrogenic Alphavirus Induces Monocyte Chemoattractant Protein-1 and Interleukin-8. Intervirology, 2000, 43, 55-60.	2.8	44
134	Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunological Reviews, 1999, 171, 27-44.	6.0	88
135	H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. European Journal of Immunology, 1999, 29, 3112-3121.	2.9	163
136	H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. , 1999, 29, 3112.		1
137	Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nature Medicine, 1998, 4, 1193-1196.	30.7	47
138	The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon $\hat{l} \pm / \hat{l}^2$ Priming. Journal of Experimental Medicine, 1998, 187, 1799-1811.	8.5	75
139	Use of recombinant vaccinia to restimulate antigen specific human peripheral blood cytotoxic T lymphocytes. Journal of Virological Methods, 1997, 65, 105-109.	2.1	3
140	Strategies Involved in Developing an Effective Vaccine for EBV-Associated Diseases. Advances in Cancer Research, 1996, 69, 213-245.	5.0	52
141	Immunological Detection of Cytoskeletal Proteins In the Exoerythrocytic Stages of Malaria By Fluorescence and Confocal Laser Scanning Microscopy. Journal of Eukaryotic Microbiology, 1993, 40, 18-23.	1.7	4
142	The specificity of recognition of a cytotoxic T lymphocyte epitope. European Journal of Immunology, 1992, 22, 191-195.	2.9	91
143	BLT esterase activity as an alternative to chromium release in cytotoxic T cell assays. Journal of Immunological Methods, 1991, 145, 43-53.	1.4	30
144	Survival and antigenic profile of irradiated malarial sporozoites in infected liver cells. Infection and Immunity, 1990, 58, 2834-2839.	2.2	43

Andreas Suhrbier

#	Article	lF	CITATIONS
145	Expression of the Precursor of the Major Merozoite Surface Antigens During the Hepatic Stage of Malaria. American Journal of Tropical Medicine and Hygiene, 1989, 40, 351-355.	1.4	31